Mysthera Therapeutics Emerges as a Trailblazer in Introducing Innovative Treatments for Autoimmune Conditions
Funding Round Info:
Mysthera Therapeutics AG, an organization dedicated to creating groundbreaking oral therapeutics for the treatment of intricate autoimmune diseases, commenced operations today. The company has secured an initial investment of $3.5 million from its founding supporter, Forty51 Ventures. This funding will facilitate the progression of its collection of pre-clinical stage pan-PIM kinase inhibitors, designed to distinctly regulate the functions of immune cells across multiple lineages.
About Mysthera Therapeutics:
Established in Basel, Switzerland, in 2023, Mysthera Therapeutics AG was brought to life through the efforts of Forty51 Ventures. With a pioneering strategy in therapeutics, Mysthera aims to revolutionize the way autoimmune diseases are treated. Through the distinctive method of PIM kinase inhibition, the company endeavors to intricately and specifically regulate the functions of immune cells spanning various lineages associated with intricate diseases. Within its portfolio, Mysthera features pre-clinical stage PIM kinase inhibitors that have been acquired under license from Inflection Biosciences Ltd.
About Forty51 Ventures:
Operating from Basel, Forty51 Ventures is a venture capital company primarily centered on fostering the creation of new enterprises and making initial investments within the biotechnology sector, with a geographic focus on Switzerland, France, and Germany. Forty51 Ventures takes the lead or shares the lead in early funding rounds (Seed and Series A) for its expanding collection of ventures, encompassing both academic and spin-out ventures from the pharmaceutical and biotech domains.